Article Text

PDF

Heartbeat: Reporting guidelines for high quality clinical cardiology research
  1. Catherine M Otto
  1. Correspondence to Professor Catherine M Otto, Division of Cardiology, University of Washington, Seattle, WA 98195, USA; cmotto{at}uw.edu

Statistics from Altmetric.com

Publication in a reputable journal is an essential step in clinical cardiovascular research. Publication allows both dissemination and archiving of research results, including details of methodology, so that other researchers and the general public can assess the reliability of the data presented. In addition to selecting the best research papers for publication, the editorial team of each journal helps ensure the quality of published research via the process of peer review and revision, formal statistical review and editorial recommendations about wording, data presentation and graphics. Additional “mechanisms to improve transparency, trial reporting and overall study quality” include clinical trial registration and adherence to defined research guideline checklists.1 In this issue of Heart, Sims and colleagues1 looked at 19 major cardiology journals' author instructions for recommendations about trial registration and research guidelines. They then looked at articles in those journals to see if the trial registration number was indicated in the final publication (figure 1). Overall, 42% of journals did not require trial registration and 37% did not recommend even a single reporting guideline. These findings suggest that more attention to trial registration and research guideline checklists is needed by other major cardiology journals. Heart does require submission of the appropriate research checklist, lists the most common guidelines and directs authors to the Equator Network website (http://www.equator-network.org/) when further information is needed. All cardiovascular researchers should be familiar with these checklists and use them in study design (not just when writing the paper), regardless of which journal publishes the final paper.

Figure 1

Frequency of published trial registry number.

Prognosis in adults with Eisenmenger syndrome (ES) is very poor and we had few therapeutic options until about 10 years ago when advanced pulmonary vasodilator therapy (AT) was shown to be safe and improve exercise capacity. However there still is little data on any potential survival benefit of AT and whether treatment effects are modulated by associated clinical factors. In an observational study of 253 patients with ES in Australia and New Zealand, Arnott and colleagues2 found a lower risk of death or heart transplantation at 1 year in those treated with AT compared with those who never  received AT (mortality rate of 4.8 vs 8.4% per year), even though patients receiving AT had more severe symptoms at baseline. Multivariable analysis showed that exposure to AT was independently associated with greater survival (figure 2).

Figure 2

Greater survival in those exposed to advanced therapy. The left panel depicts the rate of death/transplant per person year in % for those exposed to advanced therapy and those never exposed. Error bars represent 95% CI. The right panel depicts the survival HR for those exposed to advanced therapy based on Cox multivariable analysis. AT, exposure to advanced therapy during study; no AT, no exposure to advanced therapy.

In an accompanying editorial, Tay3 provides detailed tables summarising the three previous observational studies on AT for ES to put this new data in context. The current study by Arnott and colleagues has the largest proportion of patients receiving AT, the longest duration of follow-up (mean 8.3 years) and shows the benefit of AT in the sickest patients. He emphasises: “The success of this study rested partially on good coordinated systems in healthcare. The strictly mandated national level therapeutic guidelines had to be adhered to, leading to a more homogenised delivery of care while a good national registry of deaths enabled accurate mortality data to be collected.” In the future, “Randomised controlled trials should begin steering away from conventional surrogates of outcomes (eg, 6 min walk test) but focus more on harder endpoints like mortality and morbidity outcomes like in pulmonary arterial hypertension trials.”

Adults patients with a repaired tetralogy of Fallot (rTOF) often have significant pulmonic valve dysfunction, prompting consideration of pulmonic valve replacement (PVR). In a series of 977 rTOF patients, Bokma and colleagues report that the 45% of patients who had undergone PVR did not have a lower mortality or incidence of sustained ventricular tachycardia over an average follow-up of 5.3 years compared with rTOF patients without a PVR.4 In patients who did not meet consensus criteria for PVR but still had the procedure, there were more adverse events after PVR compared with patients treated (appropriately) without PVR (figure 3).

Figure 3

Event rate according to proactive and conservative criteria and pulmonary valve replacement (PVR) status. Event rates according to prespecified PVR and proactive/conservative criteria subgroups. *The PVR propensity-corrected HR of event (PVR compared with no PVR) for all patients is displayed as the overall estimate for the primary and secondary outcome. The unadjusted HR of event within subgroups is also displayed in this figure including the interaction test p value.

Latus and Tutarel5 comment in response to this data that: “The reported ‘mid-term’ outcomes shed a critical light on several aspects of our current theory regarding the time course and underlying mechanisms of right ventricular(RV) failure, arrhythmias and sudden cardiac death. If PVR seems not to improve outcome or even increases risk when performed ‘too early’, our hypothesis of an association between RV regression and improved outcome following PVR seems error prone.” They suggest that, in addition to severity of pulmonic regurgitation and RV dilation, we might also need to consider focal fibrosis and surgical scar as possible risk factors for ventricular tachycardia in rTOF patients. Perhaps risk will be lower with transcatheter, compared with surgical PVR approaches, although questions remain about valve durability and susceptibility to endocarditis.

The Education in Heart article in this issue addresses the pathophysiology, diagnosis and management of peripartum cardiomyopathy.6 Key points are to: (1) consider the diagnosis in women presenting with signs of heart failure during pregnancy to up to several months after delivery, (2) make the diagnosis with serum markers and echocardiography and (3) remember that many patients recover function within 12 months on conventional heart failure therapy with a mortality rate now <10% at 1 year. However, there is a risk of recurrence with future pregnancies—long term management should involve an interdisciplinary team with patient counselling about contraception and long-term medical therapy for heart failure (figure 4).

Figure 4

Peripartum cardiomyopathy management. BP, blood pressure; ICD, implantable cardioverter defibrillator.

A state-of-the-art review article on constrictive pericarditis by Welch7 is an invaluable guide to this uncommon, but devastating, clinical condition. Diagnosis is challenging, often delayed, and management options are not ideal (figure 5).

Figure 5

Simplified diagnostic algorithm for the diagnosis and treatment of symptomatic constrictive pericarditis. *Based on time course and clinical assessment that may include CMR MRI  and inflammatory markers.

References

View Abstract

Footnotes

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.